Literature DB >> 15876399

The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.

Yoshiyuki Yasuda1, Jadwiga Kaleta, Dieter Brömme.   

Abstract

Human cysteine proteases of the papain family have been recognized as potential drug targets for musculoskeletal diseases. Most of the interest is focused on cathepsins S and K, which display selective expression in cells of the immune system and cells capable to efficiently degrade extracellular matrix proteins, in particular collagens. The predominant expression of cathepsin K in osteoclasts has rendered the enzyme into a major target for the development of novel anti-resorptive drugs in osteoporosis whereas cathepsin S appears to be an attractive drug target candidate for various inflammatory diseases including rheumatoid arthritis. Since rheumatoid arthritis is at the same time an inflammatory and joint destructive disorder, the combined inhibition of both cathepsins S and K should be beneficial. This review will outline the rationale and recent progress for targeting cathepsins in arthritis and osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876399     DOI: 10.1016/j.addr.2004.12.013

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  77 in total

1.  Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.

Authors:  Benelita Tina Elie; Vasilena Gocheva; Tanaya Shree; Stacie A Dalrymple; Leslie J Holsinger; Johanna A Joyce
Journal:  Biochimie       Date:  2010-05-04       Impact factor: 4.079

2.  Schistosoma japonicum cystatin attenuates murine collagen-induced arthritis.

Authors:  Fang Liu; Weisheng Cheng; Faustina Pappoe; Xiaodong Hu; Huiqin Wen; Qingli Luo; Shushu Wang; Fang Deng; Yuanyuan Xie; Yuanhong Xu; Jilong Shen
Journal:  Parasitol Res       Date:  2016-07-08       Impact factor: 2.289

3.  Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites.

Authors:  Bin Yu; Dora P A J Fonseca; Sara M O'Rourke; Phillip W Berman
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

4.  Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.

Authors:  Susan Wilson; Dieter Brömme
Journal:  J Pediatr Rehabil Med       Date:  2010

5.  Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.

Authors:  C Jerome; M Missbach; R Gamse
Journal:  Osteoporos Int       Date:  2011-02-10       Impact factor: 4.507

6.  Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.

Authors:  C Jerome; M Missbach; R Gamse
Journal:  Osteoporos Int       Date:  2011-03-05       Impact factor: 4.507

7.  The pivotal role of microRNA-21 in osteoclastogenesis inhibition by anthracycline glycoside aloin.

Authors:  Radha Madhyastha; Harishkumar Madhyastha; Yutthana Pengjam; Queen Intan Nurrahmah; Yuichi Nakajima; Masugi Maruyama
Journal:  J Nat Med       Date:  2018-08-16       Impact factor: 2.343

8.  Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.

Authors:  Susan Wilson; Saadat Hashamiyan; Lorne Clarke; Paul Saftig; John Mort; Valeria M Dejica; Dieter Brömme
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

9.  Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice.

Authors:  Weifang Yu; Jian Liu; Michael A Shi; Jianan Wang; Meixiang Xiang; Shiro Kitamoto; Bing Wang; Galina K Sukhova; George F Murphy; Gabriela Orasanu; Anders Grubb; Guo-Ping Shi
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

10.  Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.

Authors:  T Nakamura; M Shiraki; M Fukunaga; T Tomomitsu; A C Santora; R Tsai; G Fujimoto; M Nakagomi; H Tsubouchi; E Rosenberg; S Uchida
Journal:  Osteoporos Int       Date:  2013-05-29       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.